It should be said at the outset that the US law is very different to that of Australia, and it is therefore unlikely that anything in Judge Brinkema’s legal reasoning will be influential upon the Full Court. It has also become apparent through the UK High Court and Court of Appeal decisions that while the UK law shares some similarities with the corresponding provisions of the Australian Patents Act 1990, there are also some significant differences. Even so, there are aspects of the reasoning of Lord Justice Arnold in the Court of Appeal that the Australian appeals court may consider persuasive, and that could therefore influence the outcome here.
There are two key questions likely to be addressed in the appeal, both of which also arose in the UK, although only the first received substantive attention in the US. These are:
Can DABUS, as an ‘AI’ machine and not a human being, validly be named as an inventor on a patent application?
Can Dr Thaler, not being (at his own insistence) the inventor, establish a proper legal basis for entitlement to the grant of patents on inventions said to be generated by DABUS?
On 27 August 2021, the Commissioner of Patents lodged an appeal (case no. VID496/2021) against the decision of Justice Beach in the Federal Court of Australia finding that the ‘AI’ machine known as DABUS could be named as sole inventor on an Australian patent application. Unusually, and presumably in recognition of the media and public interest generated by this case, IP Australia took the step of announcing the filing of the appeal, while emphasising that ‘[t]he appeal is centred on questions of law and the interpretation of the patents legislation as it currently stands’ and that ‘[t]he decision to appeal does not represent a policy position by the Australian Government on whether AI should or could ever be considered an inventor on a patent application.’ The appeal will most likely be heard by a Full Bench of the Federal Court comprising three judges, although in rare cases deemed sufficiently significant a five judge panel may be assigned. A hearing could take place as early as November this year, but at this stage it seems more likely to be scheduled for early in 2022.
These cases are, of course, of interest because they concern the fascinating question of whether non-human machines can be inventors for the purposes of obtaining patent. But they are also interesting for what they reveal about the differences between the treatment of inventors under US and UK law. In the US the inventor is central and indispensable – a position that arguably derives ultimately from the Constitutional authority for Congress to make laws ‘promote the Progress of Science and useful Arts, by securing for limited Times to Authors and Inventors the exclusive Right to their respective Writings and Discoveries’. In the UK, however – and in the view of Birss LJ in particular – the identity of the inventor is almost irrelevant in the majority of patents applied for, prosecuted and granted.
I will cover these latest developments in the DABUS saga over a series of three articles. In this first article, I will look at the approach taken to the role of the inventor in the US, how it differs from other jurisdictions, and the recent decision from the EDVA. The second article will cover the split decision in the UK, and how the differing opinions of eminent patent jurists Arnold LJ and Birss LJ stack up. Finally, in the third part I will look at where Australia sits, and consider whether either of the US and UK decisions may be of any relevance in the upcoming Full Court appeal.
In late summer 2021, athletes with disabilities from around the world competed at the Tokyo 2020 Paralympic Games. Maja Hoock, Manager of Corporate Communications Research and Development (R&D) at the leading German prosthetics company, Ottobock, explains how IP-protected sports prostheses help athletes make the most of their abilities.
New Albany, Indiana – Poulsen Roser A/S (“Poulsen”), the Plaintiff, is a family-owned company allegedly world-famous for breeding distinctive rose varieties. Apparently due to this notoriety, Poulsen obtains patent and trademark protection for its roses throughout the world, including the United States. According to the Complaint, Poulsen developed a unique currant red hybrid tea rose […]
Today, we are going to review Showell, a sales enablement and collaboration solution for modern businesses. Showell allows Sales teams to:Have access to their...
Revelation Biosciences, Inc., a clinical-stage life sciences company focused on the development of immunologic‑based therapies for the prevention and treatment of disease, and Petra Acquisition, Inc., today announced they have entered into a definitive merger agreement for a business combination that will result in Revelation becoming a publicly-traded company.
In the case of Hindustan Unilever Ltd v. An Opposing Party, the Bombay High Court called out the practice of seeking separate reliefs of injunction for passing off and infringement when pleadings were presented in respect of matters of trademark infringement.
1). Cryptocurrency Kylin Network’s (CRYPTO:KYL)($KYL) interview with Mr. Dylan Dewdney, Project Lead & Co-Founder2). GlobeX Data Ltd.’s (OTCQB:SWISF) (CSE:SWIS) (FRA:GDT) interview with Mr. Alain Ghiai, CEO3). Cryptocurrency...
With state legalization expanding and financial troubles receding, Wall Street says it’s time to pay attention to U.S. marijuana stocks. Their path to profitability is firmer than their better-hyped Canadian counterparts, analysts say. The playing field is bigger, even though cannabis isn’t federally legal yet. Sales growth for the biggest producers is stronger. And […]